{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T14:07:26Z","timestamp":1778335646383,"version":"3.51.4"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"27","license":[{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Dacomitinib-induced liver injury is often manifested by mild elevations of transaminases and bilirubin, and severe intrahepatic cholestasis caused by dacomitinib for simultaneous taking orally cytochrome P450 2D6 (CYP2D6) competitive substrates has been rarely reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>The patient was a 69-year-old woman with non\u2013small cell lung cancer (NSCLC) who was prescribed oral dacomitinib for a month; she was given oral loratadine due to \u201callergic rhinitis\u201d and metoprolol extended action tablets due to \u201ctachycardia\u201d separately for a few days during the course of dacomitinib treatment. The patient developed liver damage, increased fatigue, yellow urine, and pruritus, with significantly elevated serum levels of bilirubin and glutamyltranspetidase.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Intrahepatic cholestasis, drug-induced liver injury, and NSCLC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>After admission, the patient was prescribed adenosylmethionine, acetylcysteine, ursodeoxycholic acid capsule, methylprednisolone and fenofibrate for a month, with progressive elevation of liver biochemical parameters. Through drug enzyme gene assays in the liver tissue after percutaneous liver biopsy, we found both CYP2D6*10\/*10 and ATP-binding cassette subfamily B member 1 GG variants (rs1045642) positive. After the poor response to the conventional medication, the patient underwent plasma exchange.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient was discharged after her liver parameters improved; the parameters remained normal at several follow-up visits, and she renewed the NSCLC regimens without dacomitinib after being evaluated by oncologists.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Dacomitinib can induce severe intrahepatic cholestasis. It is considered that patients with intermediate metabolic CYP2D6 are susceptible to drug-induced liver injury caused by dacomitinib; plasma exchange may be an effective treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000029629","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T12:26:08Z","timestamp":1657283168000},"page":"e29629","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Plasma exchange treats severe intrahepatic cholestasis caused by dacomitinib: A case report"],"prefix":"10.1097","volume":"101","author":[{"given":"Fei","family":"Qiao","sequence":"first","affiliation":[{"name":"Department of Hepatology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinlei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiting","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9365-3550","authenticated-orcid":false,"given":"Nanyuan","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"key":"R1-20250504","first-page":"796","article-title":"The guideline for diagnosis and treatment of Chinese patients with sensitizing EGFR mutation or ALK fusion gene-positive non-small cell lung cancer (2015 version).","volume":"37","year":"2015","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12943-018-0777-1","article-title":"Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer.","volume":"17","author":"Wu","year":"2018","journal-title":"Mol Cancer"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41571-018-0081-4","article-title":"Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?","volume":"15","author":"Recondo","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"l5460","DOI":"10.1136\/bmj.l5460","article-title":"Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.","volume":"367","author":"Zhao","year":"2019","journal-title":"BMJ"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1200\/JCO.2018.78.7994","article-title":"Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations.","volume":"36","author":"Mok","year":"2018","journal-title":"J Clin Oncol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(14)70461-9","article-title":"Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.","volume":"15","author":"J\u00e4nne","year":"2014","journal-title":"Lancet Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1111\/cas.14384","article-title":"Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.","volume":"111","author":"Nishio","year":"2020","journal-title":"Cancer Sci"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases.","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis.","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","article-title":"British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis.","volume":"68","author":"Chapman","year":"2019","journal-title":"Gut"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/cncr.28561","article-title":"A phase 2 trial of dacomitinib (pf-00299804), an oral, irreversible pan-her (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.","volume":"120","author":"Reckamp","year":"2014","journal-title":"Cancer"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S1470-2045(14)70472-3","article-title":"Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.","volume":"15","author":"Ellis","year":"2014","journal-title":"Lancet Oncol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/jcpt.13281","article-title":"Hepatotoxicity with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer patients: a network meta-analysis.","volume":"46","author":"Wu","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (archer 1050): a randomised, open-label, phase 3 trial.","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1200\/JCO.2011.40.9433","article-title":"Randomized phase ii study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.","volume":"30","author":"Ramalingam","year":"2012","journal-title":"J Clin Oncol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1097\/JTO.0000000000000275","article-title":"Safety and efficacy of dacomitinib in Korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I\/II trial.","volume":"9","author":"Park","year":"2014","journal-title":"J Thorac Oncol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"738","DOI":"10.7326\/0003-4819-125-9-199611010-00006","article-title":"Subfulminant liver failure and severe hepatotoxicity caused by loratadine use.","volume":"125","author":"Schiano","year":"1996","journal-title":"Ann Intern Med"},{"key":"R18-20250504","first-page":"e1209","article-title":"Metoprolol-induced severe liver injury and successful management with therapeutic plasma exchange.","volume":"9","author":"Philips","year":"2017","journal-title":"Cureus"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/bcpt.13231","article-title":"Clinical toxicology of beta-blocker overdose in adults.","volume":"125","author":"Lauterbach","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.lungcan.2017.08.017","article-title":"Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers.","volume":"112","author":"Yu","year":"2017","journal-title":"Lung Cancer"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/S1470-2045(14)70452-8","article-title":"Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.","volume":"15","author":"Ramalingam","year":"2014","journal-title":"Lancet Oncol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/annonc\/mdv186","article-title":"Targeting HER2 aberrations as actionable drivers in lung cancers: phase ii trial of the pan-her tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.","volume":"26","author":"Kris","year":"2015","journal-title":"Ann Oncol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.lungcan.2015.08.004","article-title":"Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations.","volume":"90","author":"Sugiyama","year":"2015","journal-title":"Lung Cancer"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s40262-019-00750-8","article-title":"Physicochemical properties, biotransformation, and transport pathways of established and newly approved medications: a systematic review of the top 200 most prescribed drugs vs. the FDA-approved drugs between 2005 and 2016.","volume":"58","author":"Saravanakumar","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/cts.12692","article-title":"Standardizing CYP 2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and Dutch pharmacogenetics working group.","volume":"13","author":"Caudle","year":"2020","journal-title":"Clin Transl Sci"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11318030-000000000-00000","article-title":"Polymorphism of human cytochrome P450 2D6 and its clinical significance.","volume":"48","author":"Zhou","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"108840","DOI":"10.1016\/j.cbi.2019.108840","article-title":"Effects of 24 cyp2d6 variants found in Chinese population on the metabolism of clonidine in vitro.","volume":"313","author":"Li","year":"2019","journal-title":"Chem Biol Interact"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/00498254.2017.1342881","article-title":"Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6.","volume":"48","author":"Chen","year":"2018","journal-title":"Xenobiotica"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canlet.2018.01.021","article-title":"Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.","volume":"421","author":"Fan","year":"2018","journal-title":"Cancer Lett"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13046-018-0690-x","article-title":"Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.","volume":"37","author":"Guo","year":"2018","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:05:02Z","timestamp":1746331502000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":30,"journal-issue":{"issue":"27","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000029629","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,8]]}}}